LRG’s European Activities

LRG recently entered into a Joint Venture Agreement with a strategic European partner.  Our strategic partner is currently reconfiguring their System for use in live animal studies, to be followed by an EU human trial in the later part of 2018 or early 2019. When completed, the Joint Venture Company will have developed a unique prototype Multi Photon femtosecond Laser system for its ground-breaking Presbyopic procedure.

The Company is committed to following a European strategy regarding the development of it’s’ technology. This will involve establishing a separate EU corporate facility to manage their clinical/regulatory activities, to work with EU based collaborators and for business development as the Company sets up EU commercialization. It is anticipated that commercialization could occur in as little as three years from funding —including acquiring a CE Mark. This clinical and regulatory work would also be used for gaining Asian and USA market approvals.